-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Glucagon opposes the hypoglycemic effect of insulin and stimulates hepatic glucose production
Glucagon also mediates several metabolic effects not related to glucose, including regulation of amino acid metabolism (urea production); stimulation of insulin secretion; breakdown of fatty acids in the liver and inhibition of lipogenesis; potential reduction in food intake; increased energy expenditure ; and may modulate heart rate and contractility, although the latter effect may not be physiological
METHODS: A cross-sectional Holbaek study of overweight/obese children and adolescents aged 6 to 19 years was performed in the obese outpatient group (n=2154) and the normal weight group (n=1858)
Results: The level of glucagon in the obese clinical group was significantly higher than that in the human group (P<0.
Figure 1
Figure 1
Figure 2.
Figure 2.
Figure 3: Estimated ORs (95% CI) of fasting plasma glucagon as an indicator of cardiometabolic risk profile in the pooled model, adjusted for age, sex, and body mass index SDS
Figure 3: Estimated ORs (95% CI) of fasting plasma glucagon as an indicator of cardiometabolic risk profile in the pooled model, adjusted for age, sex, and body mass index SDS
Fasting glucagon concentrations were elevated in overweight/obese children and adolescents compared with normal-weight peers, which corresponded to worsening cardiometabolic risk outcomes other than hyperglycemia
Hyperglucagonemia in pediatric adiposity associates with cardiometabolic risk factors but not
hyperglycemia